| Literature DB >> 31229996 |
Bhupendar Tayal1, Claus Graff2, Christian Selmer3, Kristian Hay Kragholm4,5, Magnus Kihlstrom6, Jonas Bille Nielsen7, Anne-Marie Schjerning Olsen6, Adrian Holger Pietersen8, Anders G Holst9, Peter Søgaard10, Christine Benn Christiansen11, Jens Faber3,12, Gunnar Hilmar Gislason12,13, Christian Torp-Pedersen10,14, Steen M Hansen15.
Abstract
OBJECTIVE: The objective of the present study was to investigate associations of both overt and subclinical thyroid dysfunction with common ECG parameters in a large primary healthcare population.Entities:
Keywords: electrocardiogram; marquette 12sl; thyroid dysfunction
Mesh:
Year: 2019 PMID: 31229996 PMCID: PMC6596967 DOI: 10.1136/bmjopen-2018-023854
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Patient inclusion flow chart. Flow-chart showing the details of the inclusion process of patients for the study. TSH, thyroid-stimulating hormone.
Definitions of thyroid disease and thyroid dysfunction levels
| Thyroid dysfunction definitions | TSH | FT4 | T4T |
| Overt hyperthyroidism | <0.2 mU/L | >22 pmol/L | >140 nmol/L |
| Subclinical hyperthyroidism | <0.2 mU/L | 9–22 pmol/L | 60–140 nmol/L |
| Euthyroidism | 0.2–5.0 mU/L | 9–22 pmol/L | 60–140 nmol/L |
| Subclinical hypothyroidism | >5.0 mU/L | 9–22 pmol/L | 60–140 nmol/L |
| Overt hypothyroidism | >5.0 mU/L | <9 pmol/L | <60 nmol/L |
FT4, free thyroxine; T4T, total thyroxine; TSH, thyroid-stimulating hormone.
Baseline characteristics of study cohort
| Variable | Overt hyperthyroidism (n=821) | Subclinical hyperthyroidism (n=1452) | Euthyroidism (n=127 215) | Subclinical hypothyroidism (n=2883) | Overt hypothyroidism (n=336) |
| Age (years) | 54.0 (18.2) | 64.3 (16.4) | 52.2 (16.8) | 58.4 (16.7) | 57.7 (16.1) |
| Sex (men) | 177 (21.6) | 386 (26.6) | 64 867 (51.0) | 692 (24.0) | 89 (26.5) |
|
| |||||
| TSH (mU/L) | 0.0 (0.0) | 0.1 (0.1) | 1.6 (0.9) | 9.5 (8.3) | 64.3 (43.0) |
| Free T4 (pmol/L) | 42.2 (23.6) | 17.2 (2.6) | 15.4 (2.3) | 13.4 (2.2) | 6.1 (1.9) |
| Total T4 (pmol/L) | 200.0 (63.0) | 111.2 (19.4) | 105.5 (21.7) | 91.7 (17.9) | 39.7 (16.9) |
|
| |||||
| PVD | 9 (1.1) | 24 (1.7) | 992 (0.8) | 28 (1.0) | ≤3* |
| Heart failure | 12 (1.5) | 22 (1.5) | 1012 (0.8) | 37 (1.3) | 4 (1.2) |
| Ischaemic heart disease | 18 (2.2) | 60 (4.1) | 3295 (2.6) | 88 (3.1) | 12 (3.6) |
| MI | 10 (1.2) | 22 (1.5) | 1238 (1.0) | 36 (1.2) | 4 (1.2) |
| AF | 10 (1.2) | 25 (1.7) | 1057 (0.8) | 32 (1.1) | ≤3 |
| Arrhythmias | 9 (1.1) | 13 (0.9) | 1029 (0.8) | 32 (1.1) | ≤3 |
| CVD | 15 (1.8) | 64 (4.4) | 2281 (1.8) | 51 (1.8) | 10 (3.0) |
| Malignancy | 38 (4.6) | 59 (4.1) | 3301 (2.6) | 113 (3.9) | 13 (3.9) |
| Chronic renal failure | ≤3 | ≤3 | 109 (0.1) | 4 (0.1) | 0 (0.0) |
| Diabetes | 32 (3.9) | 69 (4.8) | 3663 (2.9) | 87 (3.0) | 10 (3.0) |
| COPD | 23 (2.8) | 54 (3.7) | 2089 (1.6) | 52 (1.8) | 8 (2.4) |
| Rheumatic disease | 6 (0.7) | 16 (1.1) | 686 (0.5) | 30 (1.0) | ≤3 |
|
| |||||
| Lithium | 0 (0.0) | ≤3 | 210 (0.2) | 9 (0.3) | ≤3 |
| Glucocorticoids | 18 (2.2) | 56 (3.9) | 2058 (1.6) | 48 (1.7) | 7 (2.1) |
| QTc-prolonging drugs | 108 (13.2) | 270 (18.6) | 18 249 (14.3) | 447 (15.5) | 51 (15.2) |
| Sotalol | ≤3 | ≤3 | 204 (0.2) | 5 (0.2) | 0 (0.0) |
| Digoxin | 9 (1.1) | 21 (1.4) | 592 (0.5) | 27 (0.9) | ≤3 |
| Amiodarone | ≤3 | ≤3 | 14 (0.0) | ≤3 | 0 (0.0) |
| Warfarin | 4 (0.5) | 11 (0.8) | 558 (0.4) | 12 (0.4) | 0 (0.0) |
| Beta-blockers | 67 (8.2) | 112 (7.7) | 7543 (5.9) | 221 (7.7) | 15 (4.5) |
| Calcium antagonist | 33 (4.0) | 137 (9.4) | 7528 (5.9) | 222 (7.7) | 19 (5.7) |
| ACE inhibitors or ARB | 47 (5.7) | 174 (12.0) | 10 823 (8.5) | 263 (9.1) | 33 (9.8) |
| Thiazides | 74 (9.0) | 209 (14.4) | 9633 (7.6) | 328 (11.4) | 41 (12.2) |
| Spironolactone | 5 (0.6) | 13 (0.9) | 577 (0.5) | 20 (0.7) | ≤3 |
| Loop diuretics | 38 (4.6) | 100 (6.9) | 3091 (2.4) | 131 (4.5) | 11 (3.3) |
*Numbers less than 3 are not reported.
AF, atrial fibrillation or atrial flutter; ARB, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; MI, myocardial infarction; PVD, peripheral vascular disease; T4, thyroxine; TSH, thyroid-stimulating hormone.
Figure 3Changes in heart rate with thyroid dysfunction by gender and age. Regression plots showing the changes in the heart rate (beats/min) with thyroid disorders based on age groups and gender. Euthyroidism is the reference group.
Figure 4Changes in QTc interval with thyroid dysfunction by gender and age. Regression plots showing the changes in the QTc interval (ms) with thyroid disorders in comparison with the euthyroidism based on age groups and gender.
Figure 5Risk of low voltage with thyroid dysfunction. Forest plot showing the risk for low-voltage on ECG with thyroid disorders in comparison with the euthyroid reference group after adjusting for age and gender.
Figure 2Mean ECG changes with thyroid dysfunction. Violin plots demonstrating the changes in the ECG parameters with thyroid dysfunction. The white box in the middle indicates the mean value and the red line indicates the trend with the changes in the thyroid status. The central blue area demonstrates the distribution of the individual parameters.
Figure 6Changes in P-wave, PR interval and QRS duration according to thyroid dysfunction. Regression plots showing the changes in the P-wave duration (ms), PR interval (ms) and QRS duration (ms) with thyroid disorder in comparison to the euthyroid reference group adjusted for age and gender.